Your browser doesn't support javascript.
loading
Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors.
Kim, Hoshin; Hauner, Darin; Laureanti, Joseph A; Agustin, Kruel; Raugei, Simone; Kumar, Neeraj.
Afiliação
  • Kim H; Physical and Computational Science Directorate, Pacific Northwest National Laboratory, Richland, WA, 99352, USA.
  • Hauner D; Earth and Biological Science Directorate, Pacific Northwest National Laboratory, Richland, WA, 99352, USA.
  • Laureanti JA; Physical and Computational Science Directorate, Pacific Northwest National Laboratory, Richland, WA, 99352, USA.
  • Agustin K; Earth and Biological Science Directorate, Pacific Northwest National Laboratory, Richland, WA, 99352, USA.
  • Raugei S; Physical and Computational Science Directorate, Pacific Northwest National Laboratory, Richland, WA, 99352, USA. simone.raugei@pnnl.gov.
  • Kumar N; Earth and Biological Science Directorate, Pacific Northwest National Laboratory, Richland, WA, 99352, USA. neeraj.kumar@pnnl.gov.
Sci Rep ; 12(1): 21037, 2022 12 05.
Article em En | MEDLINE | ID: mdl-36470873
ABSTRACT
Targeted covalent inhibition represents one possible strategy to block the function of SARS-CoV-2 Main Protease (MPRO), an enzyme that plays a critical role in the replication of the novel SARS-CoV-2. Toward the design of covalent inhibitors, we built a covalent inhibitor dataset using deep learning models followed by high throughput virtual screening of these candidates against MPRO. Two top-ranking inhibitors were selected for mechanistic investigations-one with an activated ester warhead that has a piperazine core and the other with an acrylamide warhead. Specifically, we performed a detailed analysis of the free energetics of covalent inhibition by hybrid quantum mechanics/molecular mechanics simulations. Cleavage of a fragment of the non-structured protein (NSP) from the SARS-CoV-2 genome was also simulated for reference. Simulations show that both candidates form more stable enzyme-inhibitor (E-I) complexes than the chosen NSP. It was found that both the NSP fragment and the activated ester inhibitor react with CYS145 of MPRO in a concerted manner, whereas the acrylamide inhibitor follows a stepwise mechanism. Most importantly, the reversible reaction and the subsequent hydrolysis reaction from E-I complexes are less probable when compared to the reactions with an NSP fragment, showing promise for these candidates to be the base for efficient MPRO inhibitors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Inibidores de Proteases / Proteases 3C de Coronavírus / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Inibidores de Proteases / Proteases 3C de Coronavírus / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article